Intravenous Dofetilide, Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter

Objectives. This study sought to determine the safety and efficacy of single bolus of intravenous dofetilide, pure class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Background. Dofetilide is highly selective blocker of the rapid component of the delayed rectifier current causing action potential prolongation. These effects, and preliminary clinical data, suggest that it may be effective in the treatment of atrial fibrillation and flutter. Methods. Ninety-one patients with sustained atrial fibrillation (75 patients) or flutter (16 patients) were entered into double-blind, randomized multicenter study of one of two doses of dofetilide (4 or 8 μg/kg body weight) or placebo. Results. Dofetilide effectively terminated the arrhythmi in 31% of patients receiving 8 μg/kg, statistically significant difference from those receiving 4 μg/kg (conversion rate 12.5%, p < 0.05) or placebo (no conversion, p < 0.01). Patients with atrial flutter had greater response to dofetilide (54% conversion rate) than those with atrial fibrillation (14.5% conversion rate, p < 0.001). Conclusions. Intravenous dofetilide can convert sustained atrial fibrillation or flutter to sinus rhythm. However, its efficacy is greater in flutter— response that contrasts with the poorer response seen with class I agents. This finding potentially represents an important advance in the pharmacologic termination of atrial flutter.